XENE insider buying and SEC filings, explained
Xenon Pharmaceuticals Inc. · CIK 1582313
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$1.7M
Insiders who bought
2
Sold (not marked 10b5-1)
$641K
Planned sales (10b5-1)
$21.3M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 30, 2026 | Purchase (code P) | Thomas Patrick Kelly (CFO) bought 15,000 shares at $37.32 ($560K), reported as a purchase (code P). New position of 15,000 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 1, 2026, 9:20 AM ET |
| Sep 30, 2026 | Purchase (code P) | Ian Mortimer (CEO and Director) bought 30,000 shares at $37.38 ($1.1M), reported as a purchase (code P). Holdings up 151% to 49,923 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 1, 2026, 9:19 AM ET |
| Aug 28, 2026 | Planned (10b5-1) | Christopher John Kenney (Chief Medical Officer) sold 7,068 shares at about $60.25 ($426K), marked as a 10b5-1 plan trade. Holdings down 100% to 2 shares. | SEC filing Filed Aug 31, 2026 |
| Aug 11, 2026 | Sale | Steven Gannon (Director) sold 10,000 shares at about $64.06 ($641K). Holdings down 84% to 1,870 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 13, 2026 |
| Jun 5, 2026 | Planned (10b5-1) | Gary Patou (Director) sold 1,322 shares at $53.14 ($70K), marked as a 10b5-1 plan trade. Holdings down 5% to 24,896 shares. | SEC filing Filed Jun 8, 2026 |
| Jun 5, 2026 | Planned (10b5-1) | Gillian Cannon (Director) sold 1,190 shares at $53.14 ($63K), marked as a 10b5-1 plan trade. Holdings down 45% to 1,455 shares. | SEC filing Filed Jun 8, 2026 |
| Mar 13, 2026 | Planned (10b5-1) | Christopher John Kenney (Chief Medical Officer) sold 1,410 shares at $55.23 ($78K), marked as a 10b5-1 plan trade. Holdings down 17% to 7,069 shares. | SEC filing Filed Mar 13, 2026 |
| Mar 13, 2026 | Planned (10b5-1) | Andrea DiFabio (Chief Legal Officer) sold 1,342 shares at $55.23 ($74K), marked as a 10b5-1 plan trade. Holdings down 16% to 7,301 shares. | SEC filing Filed Mar 13, 2026 |
| Mar 13, 2026 | Planned (10b5-1) | Ian Mortimer (CEO and Director) sold 7,308 shares at $55.23 ($404K), marked as a 10b5-1 plan trade. Holdings down 27% to 19,923 shares. | SEC filing Filed Mar 13, 2026 |
| Mar 10, 2026 | Planned (10b5-1) | Christopher John Kenney (Chief Medical Officer) sold 2,771 shares at $60.11 ($167K), marked as a 10b5-1 plan trade. Holdings down 37% to 4,729 shares. | SEC filing Filed Mar 11, 2026 |
| Mar 10, 2026 | Planned (10b5-1) | Andrea DiFabio (Chief Legal Officer) sold 2,607 shares at $60.11 ($157K), marked as a 10b5-1 plan trade. Holdings down 35% to 4,893 shares. | SEC filing Filed Mar 11, 2026 |
| Mar 9–10, 2026 | Planned (10b5-1) | Ian Mortimer (CEO and Director) sold 281,269 shares between Mar 9 and Mar 10 at about $60.32 ($17.0M), marked as a 10b5-1 plan trade. Holdings down 95% to 14,731 shares. | SEC filing Filed Mar 11, 2026 |
| Jan 2, 2026 | Planned (10b5-1) | Ian Mortimer (CEO and Director) sold 40,000 shares at about $44.43 ($1.8M), marked as a 10b5-1 plan trade. Holdings down 87% to 6,000 shares. | SEC filing Filed Jan 2, 2026 |
| Dec 5–8, 2025 | Planned (10b5-1) | Ian Mortimer (CEO and Director) sold 25,205 shares between Dec 5, 2025 and Dec 8, 2025 at about $45.33 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 81% to 6,000 shares. | SEC filing Filed Dec 9, 2025 |
| Nov 28, 2025 | Planned (10b5-1) | Ian Mortimer (CEO and Director) sold 97 shares at $45.01 ($4K), marked as a 10b5-1 plan trade. Holdings down <1% to 31,205 shares. | SEC filing Filed Dec 3, 2025 |
21 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
2 insiders bought in 30 days
$1.7M in purchases since Sep 30, 2026 · Purchases traded Sep 30, 2026 to Sep 30, 2026 · Closed
| Insider | Value | Traded | Source |
|---|---|---|---|
| Ian Mortimer (CEO) | $1.1M | Sep 30, 2026 | SEC filing |
| Thomas Patrick Kelly (CFO) | $560K | Sep 30, 2026 | SEC filing |
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow XENE in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.